

Remarks

Claims 3-6, 9-12, 17, 18 (first occurrence), 24 (new), 25 (new) and 26 (new) are pending in this application following amendments presented in this paper.

New Claim 24 is a combination of previous Claims 1, 7, 8, 13, 15 and 16. Additional amendments, such as the elimination of R⁸ and its definition, have been made for clarity and consistency. For example, there is no R⁸ variable in new Claim 24.

Similarly, new Claim 25 is a combination of previous Claims 2, 7, 8, 13, 15 and 16. Further, amendments have also been made for clarity and consistency as described above for new Claim 24.

New Claim 26 is based upon previous Claim 18 (first occurrence) having a single dependency rather than multiple dependency.

Clarifying amendments have been made to Claims 3, 4, 9, 10, 17 and 18 (first occurrence). The dependency of Claims 3-6, 9-12 and 18 (first occurrence) has been changed with the presentation of new Claims 24 and 25. The second occurrence of Claim 18 is denoted as cancelled consistent with an Article 34 Amendment made during the International Stage of the present application. Claim 17 is amended with the addition of the name of the compound of Example 19.

Applicants contend these amendments more clearly define the subject matter of the present invention. No new matter is believed to be added by new Claims 24, 25, 26 or any of the amendments presented.

Applicants respectfully request favorable consideration of their invention as claimed.

Respectfully submitted,

/John C. Demeter/

John C. Demeter
Attorney for Applicant(s)
Registration No. 30,167
Phone: 317-276-3785

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288